10-QPeriod: Q3 FY2017

AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2017

Filed October 26, 2017For Securities:AMGN

Summary

Amgen Inc. reported relatively flat total revenues for the third quarter of 2017 compared to the prior year, with a slight decrease in product sales offset by an increase in other revenues. Net income also remained stable, but diluted Earnings Per Share (EPS) saw a modest increase due to a reduction in outstanding shares. The company's balance sheet reflects a solid cash position and significant investments in marketable securities. Operating expenses showed a slight increase due to specific charges, but underlying efficiency improvements were noted. Amgen continued its capital return strategy through dividends and share repurchases, demonstrating confidence in future cash flows. The company is navigating patent litigations and biosimilar competition, while also facing operational challenges and expenses related to Hurricane Maria in Puerto Rico.

Financial Highlights

55 data points
Beta

Revenue

$5.77B

77.3% Gross Margin

Net Income

$2.02B

35.0% Net Margin

EPS (Diluted)

$2.76

Total Assets

$80.33B

Cash & Equivalents

$3.00B

Free Cash Flow

$3.30B

Financial Statements
Beta
Revenue$5.77B
Cost of Revenue$990.00M
Gross Profit$4.46B
SG&A Expenses$1.17B
Operating Expenses$3.33B
Operating Income$2.44B
Interest Expense$325.00M
Net Income$2.02B
EPS (Basic)$2.78
EPS (Diluted)$2.76
Shares Outstanding (Basic)728.00M
Shares Outstanding (Diluted)733.00M

Key Highlights

  • 1Total revenues for Q3 2017 were $5.77 billion, a slight decrease of 1% year-over-year, with product sales down 1% to $5.45 billion and other revenues up 8% to $320 million.
  • 2Net income for Q3 2017 was $2.021 billion, largely flat compared to $2.017 billion in Q3 2016. Diluted EPS increased by 3% to $2.76, benefiting from a reduction in weighted-average diluted shares.
  • 3Operating expenses increased by 2% to $3.33 billion, primarily due to charges related to discontinuing the development of AMG 899 and restructuring efforts, partially offset by savings from process improvements.
  • 4The company's cash and cash equivalents and marketable securities totaled $41.35 billion as of September 30, 2017, providing strong liquidity.
  • 5Amgen returned $2.53 billion to shareholders through dividends and $2.37 billion through stock repurchases during the first nine months of 2017.
  • 6The company is actively involved in various patent litigations, including those related to PCSK9 antibody, Sensipar®, and KYPROLIS®.
  • 7Amgen incurred $67 million in pre-tax expenses related to Hurricane Maria in Puerto Rico during Q3 2017, with additional expenses expected in Q4 2017.

Frequently Asked Questions

Amgen's total revenues for the third quarter of 2017 were $5.77 billion, a slight decrease of 1% compared to $5.81 billion in the third quarter of 2016. This was driven by a 1% decrease in product sales to $5.45 billion, offset by an 8% increase in other revenues to $320 million.

Hurricane Maria caused significant operational challenges in Puerto Rico. Amgen incurred $67 million in pre-tax expenses during the third quarter of 2017 related to the hurricane and expects an additional $75 million to $100 million in pre-tax expenses in the fourth quarter of 2017. Despite these challenges, the company reported that its manufacturing facilities were operational or resuming operations, and it maintained an uninterrupted supply of medicines.

Amgen is actively returning capital to shareholders through cash dividends and stock repurchases. In the first nine months of 2017, the company paid $2.53 billion in dividends and repurchased $2.37 billion of its stock. As of September 30, 2017, $1.7 billion remained available under its stock repurchase program, with an additional $5.0 billion authorized in October 2017.

Amgen is involved in several ongoing legal proceedings, including patent litigations related to its key products like PCSK9 antibody, Sensipar®, and KYPROLIS®. The company is also involved in biosimilar patent litigations and has settled some disputes, such as the one with AbbVie regarding AMJEVITA™/AMGEVITA™.